77 related articles for article (PubMed ID: 26118123)
21. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Nambiar S; Mirmohammadsadegh A; Doroudi R; Gustrau A; Marini A; Roeder G; Ruzicka T; Hengge UR
Arch Dermatol; 2005 Feb; 141(2):165-73. PubMed ID: 15724012
[TBL] [Abstract][Full Text] [Related]
22. Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient.
Ravindranath MH; Muthugounder S; Presser N
Melanoma Res; 2008 Feb; 18(1):47-55. PubMed ID: 18227708
[TBL] [Abstract][Full Text] [Related]
23. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
25. Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases.
Deichmann M; Polychronidis M; Benner A; Kleist C; Thome M; Kahle B; Helmke BM
Int J Oncol; 2004 Aug; 25(2):259-68. PubMed ID: 15254721
[TBL] [Abstract][Full Text] [Related]
26. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
You Y; Wang SH; Zhang JF; Zheng SY
Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
[TBL] [Abstract][Full Text] [Related]
27. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
28. Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions.
Nakakuma H; Horikawa K; Kawaguchi T; Hidaka M; Nagakura S; Hirai S; Kageshita T; Ono T; Kagimoto T; Iwamori M
Jpn J Clin Oncol; 1992 Oct; 22(5):308-12. PubMed ID: 1469793
[TBL] [Abstract][Full Text] [Related]
29. Glycosphingolipids in Bomirski transplantable melanomas in hamsters.
Ren SL; Slominski A; Yu RK
Cancer Res; 1989 Dec; 49(24 Pt 1):7051-6. PubMed ID: 2582447
[TBL] [Abstract][Full Text] [Related]
30. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.
Jaeger J; Koczan D; Thiesen HJ; Ibrahim SM; Gross G; Spang R; Kunz M
Clin Cancer Res; 2007 Feb; 13(3):806-15. PubMed ID: 17289871
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the functional integrity of the p53 tumor-suppressor gene in malignant melanoma.
Knopf A; Plettenberg C; Pickhard A; Bas M; Reifenberger J; Bier H; Balz V
Melanoma Res; 2011 Oct; 21(5):380-8. PubMed ID: 21691232
[TBL] [Abstract][Full Text] [Related]
32. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
34. Melanoma metastasis is associated with enhanced expression of the syntenin gene.
Helmke BM; Polychronidis M; Benner A; Thome M; Arribas J; Deichmann M
Oncol Rep; 2004 Aug; 12(2):221-8. PubMed ID: 15254681
[TBL] [Abstract][Full Text] [Related]
35. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
36. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.
Hilvo M; Denkert C; Lehtinen L; Müller B; Brockmöller S; Seppänen-Laakso T; Budczies J; Bucher E; Yetukuri L; Castillo S; Berg E; Nygren H; Sysi-Aho M; Griffin JL; Fiehn O; Loibl S; Richter-Ehrenstein C; Radke C; Hyötyläinen T; Kallioniemi O; Iljin K; Oresic M
Cancer Res; 2011 May; 71(9):3236-45. PubMed ID: 21415164
[TBL] [Abstract][Full Text] [Related]
37. Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma.
Wang R; Yan Q; Liu X; Wu J
Biochem Pharmacol; 2024 May; 223():116122. PubMed ID: 38467377
[TBL] [Abstract][Full Text] [Related]
38. Lipid droplets are a metabolic vulnerability in melanoma.
Lumaquin-Yin D; Montal E; Johns E; Baggiolini A; Huang TH; Ma Y; LaPlante C; Suresh S; Studer L; White RM
Nat Commun; 2023 Jun; 14(1):3192. PubMed ID: 37268606
[TBL] [Abstract][Full Text] [Related]
39. Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas.
Roesch A; Vogt T; Stolz W; Dugas M; Landthaler M; Becker B
Melanoma Res; 2003 Oct; 13(5):503-9. PubMed ID: 14512792
[TBL] [Abstract][Full Text] [Related]
40. Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.
Sumantran VN; Mishra P; Bera R; Sudhakar N
Pharmaceutics; 2016 Feb; 8(1):. PubMed ID: 26901218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
